Tags

Type your tag names separated by a space and hit enter

Rheumatoid arthritis.
Lancet 2009; 373(9664):659-72Lct

Abstract

Rheumatoid arthritis is a systemic, inflammatory, autoimmune disorder. Enhanced understanding of molecular pathogenesis has enabled development of innovative biological agents that target specific parts of the immune system. These treatments have changed the course and face of rheumatoid arthritis and outcomes for patients and society. New knowledge has emerged of how environmental factors interact with susceptibility genes and the immune system in the pathogenesis of a major subset of rheumatoid arthritis. Research undertaken on the longitudinal disease process and molecular pathology of joint inflammation has led to new therapeutic strategies that promote early use of disease-modifying drugs with tight disease control and distinct and quantifiable treatment goals. Today, such approaches can halt most cases of joint destruction but not all instances of joint inflammation and comorbidity. Understanding the cause and pathogenesis of different rheumatoid arthritis subsets will lead not only to individualised treatments during early phases of the illness but also, possibly, to disease prevention.

Authors+Show Affiliations

Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19157532

Citation

Klareskog, Lars, et al. "Rheumatoid Arthritis." Lancet (London, England), vol. 373, no. 9664, 2009, pp. 659-72.
Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-72.
Klareskog, L., Catrina, A. I., & Paget, S. (2009). Rheumatoid arthritis. Lancet (London, England), 373(9664), pp. 659-72. doi:10.1016/S0140-6736(09)60008-8.
Klareskog L, Catrina AI, Paget S. Rheumatoid Arthritis. Lancet. 2009 Feb 21;373(9664):659-72. PubMed PMID: 19157532.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rheumatoid arthritis. AU - Klareskog,Lars, AU - Catrina,Anca Irinel, AU - Paget,Stephen, Y1 - 2009/01/20/ PY - 2009/1/23/entrez PY - 2009/1/23/pubmed PY - 2009/3/6/medline SP - 659 EP - 72 JF - Lancet (London, England) JO - Lancet VL - 373 IS - 9664 N2 - Rheumatoid arthritis is a systemic, inflammatory, autoimmune disorder. Enhanced understanding of molecular pathogenesis has enabled development of innovative biological agents that target specific parts of the immune system. These treatments have changed the course and face of rheumatoid arthritis and outcomes for patients and society. New knowledge has emerged of how environmental factors interact with susceptibility genes and the immune system in the pathogenesis of a major subset of rheumatoid arthritis. Research undertaken on the longitudinal disease process and molecular pathology of joint inflammation has led to new therapeutic strategies that promote early use of disease-modifying drugs with tight disease control and distinct and quantifiable treatment goals. Today, such approaches can halt most cases of joint destruction but not all instances of joint inflammation and comorbidity. Understanding the cause and pathogenesis of different rheumatoid arthritis subsets will lead not only to individualised treatments during early phases of the illness but also, possibly, to disease prevention. SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/19157532/Rheumatoid_arthritis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(09)60008-8 DB - PRIME DP - Unbound Medicine ER -